Financial Performance - FYARRO recognized net product sales of $6.2 million and $11.5 million for the three and six months ended June 30, 2024, respectively[101]. - Product sales for the three months ended June 30, 2024, were $6.2 million, consistent with the same period in 2023, while sales for the six months were $11.5 million, down from $12.1 million in 2023[119]. - Selling, general, and administrative expenses decreased to $7.9 million for the three months ended June 30, 2024, from $11.8 million in 2023, and to $18.5 million for the six months from $23.0 million[120]. - Research and development expenses for the three months ended June 30, 2024, were $13.1 million, slightly down from $13.3 million in 2023, while expenses for the six months increased to $26.7 million from $24.3 million[123]. - Other income for the three months ended June 30, 2024, was $1.0 million, down from $1.6 million in 2023, and for the six months, it was $2.2 million compared to $3.2 million[125]. - The company reported net losses of $14.6 million and $18.0 million for the three months ended June 30, 2024 and 2023, respectively, and $32.9 million and $33.2 million for the six months ended June 30, 2024 and 2023, respectively[126]. - Cash used in operating activities for the six months ended June 30, 2024 was $28.8 million, compared to $38.1 million for the same period in 2023[129]. - Cash provided by investing activities for the six months ended June 30, 2024 was $7.0 million, significantly lower than $66.9 million for the same period in 2023[130]. - Cash provided by financing activities for the six months ended June 30, 2024 was $0.1 million, compared to $0.3 million for the same period in 2023[131]. - The accumulated deficit as of June 30, 2024, was $301.8 million, primarily due to research and development costs and administrative expenses[109]. - The company has an accumulated deficit of $301.8 million as of June 30, 2024[126]. Research and Development - Research and development costs are expected to increase in 2024 due to significant expenses related to the PRECISION1 trial and other clinical programs[107]. - The company plans to increase investment in research and development to advance FYARRO in additional indications through clinical trials[114]. - The company is currently enrolling patients in Phase 2 trials for advanced or recurrent endometrioid endometrial cancer and neuroendocrine tumors[108]. - The PRECISION1 trial was fully enrolled in April 2024 and is expected to be completed by the end of 2024, with results anticipated in early 2025[102]. - The company has contracts with various organizations for research and development activities, including clinical trial management and drug manufacturing[132]. Commercialization and Sales - The company has built a cross-functional commercial team and expects a decrease in commercialization expenses compared to prior periods[107]. - The decrease in product sales for the six months ended June 30, 2024, was attributed to distributor ordering patterns and fewer new patient initiations[119]. - Royalties on net product sales under the BMS License Agreement were $0.5 million for the three months ended June 30, 2024, consistent with the same period in 2023[103]. - A payment of $5.8 million to BMS is due no later than August 26, 2024, under the BMS License Agreement[108]. - The EOC arbitration process is expected to yield a decision in the second half of 2024, which may significantly impact sales, general, and administrative expenses[108]. Cash and Financial Position - As of June 30, 2024, the company had $78.6 million in cash, cash equivalents, and short-term investments, expected to fund operations into Q4 2025[109]. - The company has a shelf registration statement allowing it to sell up to $150.0 million of various securities, providing flexibility for future capital needs[127]. - The company entered into a lease for 10,615 square feet of office space in Morristown, New Jersey, with a term of seventy-three months[132]. Collaboration and Partnerships - The company terminated its collaboration with Mirati Therapeutics in May 2024, discontinuing enrollment in the Phase 1/2 trial[102].

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.94%. A quarter ago, it was expected that this company would post a loss of $0.66 per share when it actually produced a loss of $0.68, delivering a surprise of -3.03%.Over the last four quarters, the company has su ...

PRESS RELEASE Exhibit 99.1 Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES, CA, August 7, 2024 – Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing thera ...

FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growthInterim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024Conference call to be held today at 8:30 am EDTLOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 3 ...

Company to Host Conference Call and Webcast on August 7, 2024LOS ANGELES, July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates.Conferenc ...

LOS ANGELES, May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, announced today participation in the Jefferies Healthcare Conference, taking place June 5-6, 2024, in New York. Dave Lennon, Ph.D., President and CEO, will participate in a fireside chat on Wednesday, June 5, 2024, from 2:00 PM – 2:25 PM EDT.The fireside chat will be webcast live on ...

nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft modelData support further clinical exploration of nab-sirolimus as a single agent or in combination LOS ANGELES, May 23, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-385 ...

Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Dave Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Joseph Catanzaro - Piper Sandler Tara Bancroft - TD Cowen Ahu Demir - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Aadi Bioscien ...

PRESS RELEASE Exhibit 99.1 Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES, CA, May 8, 2024 – Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-sta ...